Table 1.

Comparison of the main pharmacokinetic parameters of levofloxacin in two groups of HIV-positive patients and in healthy subjectsa

Subject groupPharmacokinetic parameter (mean ± SD)
Cmax (μg/ml)Tmax(h)AUC0–24 (μg · h/ml)Css, avc (μg/ml)Ctrough (μg/ml)CL/Ft1/2(h)d
liter/h/kgliter/h
Levofloxacin + NFVb (n = 12)6.22 ± 1.981.4 ± 0.4571.8 ± 32.452.99 ± 1.351.5 ± 1.130.152 ± 0.1119.54 ± 8.08.6 ± 2.13
Levofloxacin + EFVb (n = 12)5.75 ± 0.823.3 ± 1.165.51 ± 20.62.95 ± 1.480.86 ± 0.50.136 ± 0.0568.7 ± 5.07.5 ± 2.6
Healthy subjects6.55 ± 1.841.17 ± 0.5253.5 ± 10.32.23 ± 0.43NRe9.69 ± 2.087.95 ± 1.35
  • a Data on healthy subjects are from Child et al. (4).

  • b Values normalized to a dose of 8 mg/kg of body weight.

  • c Css, av, average plasma drug concentration during the dosing interval at steady state.

  • d t1/2, terminal disposition half-life.

  • e NR, not reported.